REG - Goldman Sachs (EPT) Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI)
RNS Number : 5217MGoldmanSachs International08 January 2019
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
(GS) GOLDMAN SACHS INTERNATIONAL
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(c) Name of the party to the offer with which exempt principal trader is connected:
SHIRE PLC
(d) Date dealing undertaken:
07 January 2019
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - disclosed previously for SHIRE PLC
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/ sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
Purchases
730,913
25,0004,065.0000 JPY
36.7784 USD3,940.0000 JPY
36.7784 USDOrdinary
Sales
1,647,490
4,079.0000 JPY
3,921.1923 JPY
ADR / (1.00 : 0.50)
Purchases
9,000 (4,500)
18.5849 USD
18.5849 USD
ADR / (1.00 : 0.50)
Sales
9,000 (4,500)
18.5849 USD
18.5849 USD
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
Reducing a long position
3,621
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
6,142
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
9,474
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
1,590
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
1,796
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
1,106
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
8,729
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
24,098
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
2,207
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
663
3,940.0000 JPY
Ordinary
CFD
Reducing a long position
5,574
3,940.0000 JPY
Ordinary
CFD
Increasing a short position
7,300
3,978.2833 JPY
Ordinary
CFD
Increasing a short position
1,700
3,978.2833 JPY
Ordinary
CFD
Reducing a short position
800
3,985.8000 JPY
Ordinary
CFD
Reducing a short position
200
3,985.8000 JPY
Ordinary
CFD
Reducing a long position
2,400
3,985.8562 JPY
Ordinary
CFD
Reducing a long position
5,600
3,985.8562 JPY
Ordinary
CFD
Opening a long position
1,508
3,995.0000 JPY
Ordinary
CFD
Reducing a long position
1,508
3,995.0000 JPY
Ordinary
CFD
Opening a long position
7,056
3,995.0000 JPY
Ordinary
CFD
Reducing a long position
7,056
3,995.0000 JPY
Ordinary
CFD
Reducing a short position
100
4,012.7338 JPY
Ordinary
CFD
Reducing a short position
200
4,012.7338 JPY
Ordinary
SWAP
Reducing a long position
21,959
36.7784 USD
Ordinary
SWAP
Reducing a long position
3,041
36.7784 USD
Ordinary
SWAP
Opening a long position
1,400
3,968.9679 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
ADR / (1.00 : 0.50)
Call Option / (1.00 : 50.00)
Purchasing
20 (1,000)
15.0000 USD
AMERICAN
18/01/2019
3.4000 USD
ADR / (1.00 : 0.50)
Call Option / (1.00 : 50.00)
Purchasing
20 (1,000)
15.0000 USD
AMERICAN
18/01/2019
3.5000 USD
ADR / (1.00 : 0.50)
Call Option / (1.00 : 50.00)
Purchasing
20 (1,000)
15.0000 USD
AMERICAN
18/01/2019
3.3000 USD
ADR / (1.00 : 0.50)
Call Option / (1.00 : 50.00)
Purchasing
20 (1,000)
17.5000 USD
AMERICAN
18/01/2019
1.1000 USD
Ordinary
Call Option
Purchasing
366,500
4,200.0000 JPY
EUROPEAN
11/04/2019
160.9000 JPY
Ordinary
Call Option
Purchasing
366,500
4,200.0000 JPY
EUROPEAN
11/04/2019
160.9000 JPY
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising / exercised against
Number of securities
Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
NONE
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
NONE
Date of disclosure:
08 January 2019
Contact name:
Kashif Rafiq and Papa Lette
Telephone number:
+44(20) 7051 0547 / +44(20) 7774 7442
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFERBBGDBSDGBGCI
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement